Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant doxorubicin + docetaxel for locally advanced breast cancer
ACTRN12606000305527Phase 2Active, not recruiting
- Sponsor
- Cancer Council Victoria
- Start
- Aug 2000
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and docetaxel in breast cancer, sponsored by Cancer Council Victoria. Primary endpoints: Time to clinical response, Pathologic response rate and 1 more. Started Aug 2000; status: active, not recruiting.
02
Drugs
doxorubicindocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12606000305527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000305527.